US Bancorp’s Caris Life Sciences CAI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.76K Sell
211
-1,300
-86% -$23.3K ﹤0.01% 3734
2026
Q1
$27K Sell
1,511
-11,478
-88% -$251K ﹤0.01% 2973
2025
Q4
$350K Buy
12,989
+267
+2% +$7.52K ﹤0.01% 1732
2025
Q3
$385K Buy
12,722
+854
+7% +$27.2K ﹤0.01% 1658
2025
Q2
$317K Buy
+11,868
New +$320K ﹤0.01% 1758

Other funds holding CAI

US Bancorp's CAI Position: Q2 2026 in Review

US Bancorp reduced its Caris Life Sciences (CAI) stake by 86% in Q2 2026, selling an estimated $23.3K and leaving 211 shares worth $3.76K. The position accounts for ﹤0.01% of the portfolio, ranked #3734.

US Bancorp first reported a position in CAI in Q2 2025 and has held it in 5 quarters since. The position peaked at $385K in Q3 2025. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • US Bancorp held 211 shares of Caris Life Sciences worth $3.76K as of Q2 2026.
  • US Bancorp sold 1,300 Caris Life Sciences shares in Q2 2026, an estimated $23.3K.
  • Caris Life Sciences made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3734 holding.
  • US Bancorp first reported a position in Caris Life Sciences in Q2 2025 and has held it in 5 quarters since.
  • US Bancorp's Caris Life Sciences position peaked at $385K in Q3 2025.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.